Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Perspective: assembly line immunotherapy.

Literature DB >> 23803946

Perspective: assembly line immunotherapy.

Bruce L Levine¹, Carl H June.

Abstract

Mesh：

Substances：

Year: 2013 PMID： 23803946 DOI： 10.1038/498S17a

Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962

× No keyword cloud information.

4 in total

1. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

Authors: David L Porter; Bruce L Levine; Michael Kalos; Adam Bagg; Carl H June
Journal: N Engl J Med Date: 2011-08-10 Impact factor: 91.245

2. Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation.

Authors: B L Levine; J D Mosca; J L Riley; R G Carroll; M T Vahey; L L Jagodzinski; K F Wagner; D L Mayers; D S Burke; O S Weislow; D C St Louis; C H June
Journal: Science Date: 1996-06-28 Impact factor: 47.728

3. Companies ponder how truly 'personal' medicines can get.

Authors: Monya Baker
Journal: Nat Med Date: 2011-05 Impact factor: 53.440

4. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors: Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal: N Engl J Med Date: 2013-03-25 Impact factor: 91.245

4 in total

20 in total

1. Combining drugs and biologics to treat nasopharyngeal cancer.

Authors: Helen E Heslop
Journal: Mol Ther Date: 2014-01 Impact factor: 11.454

Review 2. Antibody-modified T cells: CARs take the front seat for hematologic malignancies.

Authors: Marcela V Maus; Stephan A Grupp; David L Porter; Carl H June
Journal: Blood Date: 2014-02-27 Impact factor: 22.113

3. Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance.

Authors: Federico Pietrocola; Jonathan Pol; Erika Vacchelli; Shuan Rao; David P Enot; Elisa E Baracco; Sarah Levesque; Francesca Castoldi; Nicolas Jacquelot; Takahiro Yamazaki; Laura Senovilla; Guillermo Marino; Fernando Aranda; Sylvère Durand; Valentina Sica; Alexis Chery; Sylvie Lachkar; Verena Sigl; Norma Bloy; Aitziber Buque; Simonetta Falzoni; Bernhard Ryffel; Lionel Apetoh; Francesco Di Virgilio; Frank Madeo; Maria Chiara Maiuri; Laurence Zitvogel; Beth Levine; Josef M Penninger; Guido Kroemer
Journal: Cancer Cell Date: 2016-07-11 Impact factor: 31.743

Perspective: assembly line immunotherapy.

1. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

2. Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation.

3. Companies ponder how truly 'personal' medicines can get.

4. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

1. Combining drugs and biologics to treat nasopharyngeal cancer.

Review 2. Antibody-modified T cells: CARs take the front seat for hematologic malignancies.

3. Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance.

Review 4. Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf.

Review 5. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.

Review 6. Emerging Cellular Therapies for Cancer.

7. Koch Institute Symposium on Cancer Immunology and Immunotherapy.

Review 8. Adoptive immunotherapy for cancer or viruses.

Review 9. Engineered T cells for cancer therapy.

Review 10. Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.